[{"id":"586870f5-0132-4c9b-9469-6d1bb21374ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05278728","created_at":"2022-03-14T13:54:05.742Z","updated_at":"2025-02-25T16:32:54.217Z","phase":"Phase 1/2","brief_title":"Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer","source_id_and_acronym":"NCT05278728","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" KRAS • RAS","pipe":"","alterations":" ","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • TheraCIM (nimotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2025-02-07"},{"id":"ace74252-54a3-493a-b223-6a52f7db4913","acronym":"","url":"https://clinicaltrials.gov/study/NCT06770452","created_at":"2025-02-26T06:54:41.243Z","updated_at":"2025-02-26T06:54:41.243Z","phase":"Phase 2","brief_title":"HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","source_id_and_acronym":"NCT06770452","lead_sponsor":"Zhejiang University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • HRS-4642"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-01-13"},{"id":"1daf6999-85a4-40e2-a654-9f006189a6d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02395016","created_at":"2021-01-18T11:25:27.200Z","updated_at":"2024-07-02T16:35:11.490Z","phase":"Phase 3","brief_title":"A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02395016","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • TheraCIM (nimotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2024-04-04"},{"id":"470b1556-c556-4764-aec0-fd65bb7bee1e","acronym":"NOTABLE-308","url":"https://clinicaltrials.gov/study/NCT06343116","created_at":"2024-04-02T17:41:44.202Z","updated_at":"2024-07-02T16:35:11.906Z","phase":"Phase 3","brief_title":"Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06343116 - NOTABLE-308","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil) • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-04-02"},{"id":"ce74a2bd-b0b5-477e-9e90-292a69fe06b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02947386","created_at":"2021-01-18T14:28:12.329Z","updated_at":"2024-07-02T16:35:34.575Z","phase":"Phase 1/2","brief_title":"Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02947386","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR expression • ALK rearrangement","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR expression • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • TheraCIM (nimotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 06/29/2017","start_date":" 06/29/2017","primary_txt":" Primary completion: 04/15/2021","primary_completion_date":" 04/15/2021","study_txt":" Completion: 09/08/2022","study_completion_date":" 09/08/2022","last_update_posted":"2023-10-05"},{"id":"12b49972-5a2a-42ac-8778-f1b01b3babed","acronym":"","url":"https://clinicaltrials.gov/study/NCT06048913","created_at":"2023-09-21T14:10:56.196Z","updated_at":"2024-07-02T16:35:36.159Z","phase":"Phase 1","brief_title":"Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age","source_id_and_acronym":"NCT06048913","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraCIM (nimotuzumab)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 45","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-09-21"},{"id":"5bec0696-6933-431c-a87d-bd8f954d4389","acronym":"","url":"https://clinicaltrials.gov/study/NCT06022276","created_at":"2023-09-01T17:11:46.994Z","updated_at":"2024-07-02T16:35:38.278Z","phase":"","brief_title":"Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors","source_id_and_acronym":"NCT06022276","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • CDKN2A negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraCIM (nimotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-01"},{"id":"328e86c2-f909-458a-bfed-3477f5be5a6e","acronym":"NOTABLE-307","url":"https://clinicaltrials.gov/study/NCT05978050","created_at":"2023-08-07T14:08:43.635Z","updated_at":"2024-07-02T16:35:40.808Z","phase":"Phase 3","brief_title":"Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma","source_id_and_acronym":"NCT05978050 - NOTABLE-307","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 354","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-08-07"},{"id":"c75ce7ba-142f-46df-b8c1-79c5f43f603f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05803915","created_at":"2023-04-07T14:03:42.669Z","updated_at":"2025-02-25T16:27:17.844Z","phase":"Phase 2","brief_title":"Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy","source_id_and_acronym":"NCT05803915","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 03/10/2026","study_completion_date":" 03/10/2026","last_update_posted":"2023-04-07"},{"id":"f1782f70-a36d-4e24-9569-a84aab50efe3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05772208","created_at":"2023-03-16T14:02:45.730Z","updated_at":"2024-07-02T16:35:53.150Z","phase":"Phase 3","brief_title":"Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy","source_id_and_acronym":"NCT05772208","lead_sponsor":"Fudan University","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • AiRuiKa (camrelizumab) • TheraCIM (nimotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 459","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2023-03-16"},{"id":"5b9ee356-e0b2-4831-a579-9ca8fad11cd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03837808","created_at":"2021-01-18T18:56:41.330Z","updated_at":"2024-07-02T16:36:00.841Z","phase":"Phase 3","brief_title":"Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT03837808","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • TheraCIM (nimotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 384","initiation":"Initiation: 04/11/2019","start_date":" 04/11/2019","primary_txt":" Primary completion: 02/11/2024","primary_completion_date":" 02/11/2024","study_txt":" Completion: 02/11/2024","study_completion_date":" 02/11/2024","last_update_posted":"2022-11-07"},{"id":"f07f552e-5152-459d-9e9c-70cd2e5a9a07","acronym":"","url":"https://clinicaltrials.gov/study/NCT05508347","created_at":"2022-08-19T17:10:11.498Z","updated_at":"2024-07-02T16:36:05.109Z","phase":"Phase 2","brief_title":"Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT05508347","lead_sponsor":"Sichuan Cancer Hospital and Research Institute","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • TheraCIM (nimotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 08/15/2022","start_date":" 08/15/2022","primary_txt":" Primary completion: 09/15/2023","primary_completion_date":" 09/15/2023","study_txt":" Completion: 09/15/2023","study_completion_date":" 09/15/2023","last_update_posted":"2022-08-19"},{"id":"0f520337-0cec-472e-b063-27456f36d835","acronym":"","url":"https://clinicaltrials.gov/study/NCT05351762","created_at":"2022-04-28T16:57:05.400Z","updated_at":"2024-07-02T16:36:07.840Z","phase":"Phase 2","brief_title":"Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC","source_id_and_acronym":"NCT05351762","lead_sponsor":"Xijing Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR positive • CDKN2A negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR positive • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Aqupla (nedaplatin) • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2022-07-04"},{"id":"433b0ed5-b7bd-40ad-869d-1ed1411fc5f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316480","created_at":"2022-04-07T12:57:05.926Z","updated_at":"2024-07-02T16:36:13.809Z","phase":"Phase 2","brief_title":"Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms","source_id_and_acronym":"NCT05316480","lead_sponsor":"Fudan University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2022-04-07"},{"id":"ce6668ef-0e99-4199-856e-07b1bfdf0be2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05167643","created_at":"2021-12-22T19:15:20.133Z","updated_at":"2024-07-02T16:36:13.476Z","phase":"","brief_title":"H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study","source_id_and_acronym":"NCT05167643","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • PGR positive • HR positive + HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • PGR positive • HR positive + HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • TheraCIM (nimotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/23/2022","start_date":" 01/23/2022","primary_txt":" Primary completion: 10/23/2022","primary_completion_date":" 10/23/2022","study_txt":" Completion: 08/23/2024","study_completion_date":" 08/23/2024","last_update_posted":"2022-04-07"},{"id":"f4b618b1-1a81-4884-ae4b-b89f610df253","acronym":"","url":"https://clinicaltrials.gov/study/NCT04223024","created_at":"2021-01-18T20:33:12.727Z","updated_at":"2024-07-02T16:36:19.837Z","phase":"Phase 2","brief_title":"Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT04223024","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • TheraCIM (nimotuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 246","initiation":"Initiation: 12/12/2019","start_date":" 12/12/2019","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2021-12-06"},{"id":"a9a7a7bf-6973-4daf-8343-9f7eee9b2cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04456322","created_at":"2021-01-18T21:25:51.625Z","updated_at":"2024-07-02T16:36:21.107Z","phase":"Phase 3","brief_title":"Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT04456322","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • TheraCIM (nimotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 326","initiation":"Initiation: 07/06/2020","start_date":" 07/06/2020","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2021-11-05"},{"id":"4af71c00-ace8-4969-94d5-7875335d00f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024019","created_at":"2021-08-27T13:53:06.956Z","updated_at":"2024-07-02T16:36:25.746Z","phase":"Phase 2","brief_title":"Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery","source_id_and_acronym":"NCT05024019","lead_sponsor":"Eye \u0026 ENT Hospital of Fudan University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • CDKN2A negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 08/21/2021","start_date":" 08/21/2021","primary_txt":" Primary completion: 08/21/2025","primary_completion_date":" 08/21/2025","study_txt":" Completion: 08/21/2025","study_completion_date":" 08/21/2025","last_update_posted":"2021-08-27"},{"id":"13e117fb-321d-4618-9778-cf0f7f1defb6","acronym":"CIMAHOPE","url":"https://clinicaltrials.gov/study/NCT03413579","created_at":"2021-01-18T16:50:28.373Z","updated_at":"2024-07-02T16:36:25.824Z","phase":"Phase 3","brief_title":"Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom","source_id_and_acronym":"NCT03413579 - CIMAHOPE","lead_sponsor":"El Kendi Pharmaceuticals Manufacturing Company","biomarkers":" EGFR • BCL2","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • vinorelbine tartrate • TheraCIM (nimotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-08-25"},{"id":"91ced796-d298-4eaf-8656-d57ac827dca2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03766178","created_at":"2021-01-18T18:38:10.699Z","updated_at":"2024-07-02T16:36:28.279Z","phase":"Phase 2","brief_title":"Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT03766178","lead_sponsor":"The First Affiliated Hospital of Zhengzhou University","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-07-07"},{"id":"1c586608-59d9-4781-bd22-d5ed3b53761a","acronym":"Carpp-1","url":"https://clinicaltrials.gov/study/NCT04882462","created_at":"2021-05-12T12:52:44.721Z","updated_at":"2024-07-02T16:36:30.419Z","phase":"Phase 2","brief_title":"Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.","source_id_and_acronym":"NCT04882462 - Carpp-1","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2021-05-12"},{"id":"70f335fc-9b8b-4623-89db-8c1741d28b27","acronym":"","url":"https://clinicaltrials.gov/study/NCT04136600","created_at":"2021-01-18T20:18:20.744Z","updated_at":"2024-07-02T16:36:36.730Z","phase":"Phase 2","brief_title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","source_id_and_acronym":"NCT04136600","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • capecitabine • oxaliplatin • TheraCIM (nimotuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 08/31/2021","primary_completion_date":" 08/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-12-30"},{"id":"7f6de506-a7e6-4707-9fc0-55d397684a95","acronym":"","url":"https://clinicaltrials.gov/study/NCT03557112","created_at":"2021-01-18T17:30:31.680Z","updated_at":"2024-07-02T16:37:05.643Z","phase":"Phase 2","brief_title":"By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC","source_id_and_acronym":"NCT03557112","lead_sponsor":"Guiyang Medical University","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • TheraCIM (nimotuzumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 180","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2018-11-02"},{"id":"c19f4f8d-399e-47b4-97ff-3f847081a79e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03469531","created_at":"2021-01-18T17:05:58.269Z","updated_at":"2024-07-02T16:37:07.967Z","phase":"Phase 2","brief_title":"Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer","source_id_and_acronym":"NCT03469531","lead_sponsor":"Zhujiang Hospital","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • TheraCIM (nimotuzumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 03/10/2021","primary_completion_date":" 03/10/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2018-08-13"}]